Drugs / hA-MSCs
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07115082 | Oct 2024 → Dec 2025 overdue | primary ovarian failure | Yan Hongli | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hA-MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07115082 ↗ |
| Known as | human amniotic membrane mesenchymal stem cells | “human amniotic membrane mesenchymal stem cells (hA-MSCs)” NCT07115082 ↗ |
| Route | Intravenous | “Human amniotic MSCs were infused back into the patients by intravenous injection.” NCT07115082 ↗ |